TG Therapeutics Inc TGTX revealed preliminary BRIUMVI U.S. net product sales for Q4 and FY23.
The expected BRIUMVI U.S. net product revenue for Q4 is around $40 million and $89 million for FY23.
The company anticipates a year-end 2023 cash position of about $215 million.
Prospects: TGTX envisions BRIUMVI U.S. net product revenue of $41 million-$46 million in Q1 and $220 million-$260 million for FY24.
The company aims to achieve operating expenses of approximately $250 million in FY24.
In FY24, TGTX plans to commence clinical development of subcutaneous BRIUMVI and initiate a trial evaluating BRIUMVI in autoimmune diseases beyond Multiple Sclerosis (MS).
Additionally, the company plans to commence a trial for evaluating azer-cel in autoimmune disease and present data from the ENHANCE Phase 3b CD20 switch trial at multiple conferences this year.
Yesterday, TGTX entered into a deal with Precision BioSciences, Inc. DTIL to acquire a worldwide license to Precision’s Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy program for autoimmune diseases and all other non-oncology indications.
As of Q3 FY23, TG Therapeutics’ cash position stood at $229.2 million.
Price Movement: TGTX shares are up 10.52% at $23.22 premarket on the last check Wednesday.
